We are live on ! Find out more

485 hedge funds and large institutions have $11.4B invested in Sanofi in 2017 Q3 according to their latest regulatory filings, with 50 funds opening new positions, 145 increasing their positions, 171 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 35

2% more funds holding

Funds holding: 475485 (+10)

1% more capital invested

Capital invested by funds: $11.3B → $11.4B (+$136M)

0.52% less ownership

Funds ownership: 18.66%18.15% (-0.52%)

10% less funds holding in top 10

Funds holding in top 10: 109 (-1)

11% less call options, than puts

Call options by funds: $32.6M | Put options by funds: $36.5M

15% less repeat investments, than reductions

Existing positions increased: 145 | Existing positions reduced: 171

Holders
485
Holders Change
+10
Holders Change %
+2.11%
% of All Funds
12.06%
Holding in Top 10
9
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-10%
% of All Funds
0.22%
New
50
Increased
145
Reduced
171
Closed
35
Calls
$32.6M
Puts
$36.5M
Net Calls
-$3.88M
Net Calls Change
-$82.3M

SNY Hedge Fund Activity: Q3 2017 in Review

485 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Sanofi (SNY) for Q3 2017, worth a combined $11.4B — up 1.2% from $11.3B a quarter earlier.

Buyers outnumbered sellers: 50 funds opened new SNY positions and 35 closed out — a net gain of 15 holders — while 145 added to existing stakes and 171 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $109M. The largest seller was Capital World Investors, exiting entirely with an estimated $105M sold.

  • 485 institutional investors held Sanofi (SNY) as of Q3 2017, up from 475 in Q2 2017.
  • Funds reported $11.4B of Sanofi stock for Q3 2017, up 1.2% quarter-over-quarter.
  • 50 funds opened new Sanofi positions in Q3 2017 and 35 closed out, a net change of +15 holders.
  • The largest Sanofi buyer in Q3 2017 was Fidelity Investments, an estimated $109M added.
  • The largest Sanofi seller in Q3 2017 was Capital World Investors, an estimated $105M sold.

Based on aggregated 13F filings for Q3 2017.